Skip to main content

Reneo Pharmaceuticals Stock Forecast, Price & News

-1.32 (-10.59 %)
(As of 05/12/2021 12:00 AM ET)
Today's Range
50-Day Range N/A
52-Week Range
Volume45,733 shs
Average Volume93,823 shs
Market Capitalization$269.95 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive RPHM News and Ratings via Email

Sign-up to receive the latest news and ratings for Reneo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Reneo Pharmaceuticals

Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. The company was incorporated in 2014 and is headquartered in San Diego, California.


See More Headlines

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolNASDAQ:RPHM
Year FoundedN/A

Sales & Book Value

Annual SalesN/A





Market Cap$269.95 million
Next Earnings DateN/A
OptionableNot Optionable


Overall MarketRank

2.03 out of 5 stars

Medical Sector

53rd out of 2,042 stocks

Biotechnology Industry

6th out of 158 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Reneo Pharmaceuticals (NASDAQ:RPHM) Frequently Asked Questions

Is Reneo Pharmaceuticals a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Reneo Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Reneo Pharmaceuticals stock.
View analyst ratings for Reneo Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Reneo Pharmaceuticals?

Wall Street analysts have given Reneo Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Reneo Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for RPHM?

3 brokers have issued 12-month price targets for Reneo Pharmaceuticals' stock. Their forecasts range from $24.00 to $45.00. On average, they anticipate Reneo Pharmaceuticals' stock price to reach $31.33 in the next year. This suggests a possible upside of 181.0% from the stock's current price.
View analysts' price targets for Reneo Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Reneo Pharmaceuticals' key executives?

Reneo Pharmaceuticals' management team includes the following people:
  • Mr. Michael G. Grey, Founder & Exec. Chairman (Age 68)
  • Mr. Gregory J. Flesher, Pres & CEO (Age 51)
  • Mr. Vineet R. Jindal, Chief Financial Officer
  • Ms. Wendy S. Johnson, Chief Operating Officer (Age 69)
  • Dr. Alejandro Dorenbaum, Chief Medical Officer (Age 60)
  • Mr. Michael Cruse, Sr. VP of Corp. Operations
  • Deborah J. Tower, Sec.

Who are some of Reneo Pharmaceuticals' key competitors?

When did Reneo Pharmaceuticals IPO?

(RPHM) raised $101 million in an initial public offering on Friday, April 9th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

What is Reneo Pharmaceuticals' stock symbol?

Reneo Pharmaceuticals trades on the NASDAQ under the ticker symbol "RPHM."

When does the company's quiet period expire?

Reneo Pharmaceuticals' quiet period expires on Wednesday, May 19th. Reneo Pharmaceuticals had issued 6,250,000 shares in its public offering on April 9th. The total size of the offering was $93,750,000 based on an initial share price of $15.00. During the company's quiet period, insiders and underwriters involved in the IPO are restricted from issuing any research reports for the company because of SEC regulations. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of Reneo Pharmaceuticals?

Shares of RPHM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Reneo Pharmaceuticals' stock price today?

One share of RPHM stock can currently be purchased for approximately $11.15.

How much money does Reneo Pharmaceuticals make?

Reneo Pharmaceuticals has a market capitalization of $269.95 million.

How many employees does Reneo Pharmaceuticals have?

Reneo Pharmaceuticals employs 12 workers across the globe.

What is Reneo Pharmaceuticals' official website?

The official website for Reneo Pharmaceuticals is

How can I contact Reneo Pharmaceuticals?

The company can be reached via phone at 858-283-0280.

This page was last updated on 5/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.